This section is intended for healthcare professionals outside of the US only. If you are a patient or a carer, please click here for further information.

Management of Niemann-Pick type C disease

As Niemann-Pick type C disease (NP-C) is a progressive disease, early diagnosis is critical to ensure that patients can start disease-specific therapy in order to stabilize or delay disease progression and preserve function and quality of life, which without a cure are the best attainable treatment goals for NP-C. Management strategies also include non-specific, symptomatic treatments.1

Disease-specific therapy

Recent advances in the understanding of NP-C pathophysiology have led to the development of a NP-C-specific treatment that can have an impact on disease progression. In January 2009, a glycosphingolipid synthesis inhibitor called Zavesca® (miglustat) was approved in the European Union (EU) and is now available in a total of 43 countries, for the treatment of progressive neurological manifestations in adult and pediatric patients with NP-C.2 By inhibiting the enzyme glucosylceramide synthase, this therapy prevents the synthesis of glycosphingolipids and in doing so reduces the accumulation of these lipids in patients with NP-C. It has been shown that miglustat can improve or stabilize key parameters of progressive neurological disease in children, juveniles and adult patients, including horizontal saccadic eye movement (HSEM) velocity, ability to swallow, auditory acuity, ambulation, manipulation and language.3-5

Extension treatment studies have shown that therapeutic benefits of miglustat were maintained for the entire observational period of up to 48 months.6

Disease-specific therapy should be initiated at the earliest sign of neurological disease onset in order to optimize treatment outcomes.1

The most frequently reported adverse events of miglustat therapy were mild or moderate diarrhea, flatulence, abdominal pain, weight loss and tremor.2 Gastrointestinal disturbances and weight loss tend to decrease over time on continued therapy and can be managed by dietary modification where foods containing disaccharides are reduced, temporary dose reduction or co-administration of probiotics such as saccharomyces boulardii and symptomatic therapy, such as loperamide.2

The Summary of Product Characteristics provides guidance on the use of Zavesca® (miglustat) in patients with NP-C.2


Symptomatic therapies

Symptomatic therapies may be at least partially successful in treating some symptoms of NP-C. Although they have no impact on disease progression or long-term outcomes, they can improve the patient’s quality of life. The main approaches to management of the visceral, neurological and psychiatric symptoms of NP-C are summarized in Figure 1.1

Figure 1: Symptomatic treatment of NP-C1

Symptoms Treatment
Visceral (systemic) symptoms  
Gastrointestinal disturbances Anti-propulsive agents, such as loperamide for diarrhea; a bowel management programme to prevent constipation
Lung symptoms Aggressive bronchodilatation; chest physical therapy
Neurological symptoms  
Dysphagia/feeding problems

Softening or thickening of food; gastrostomy


Oral atropine; parotid or sub-malar injections of botulinum toxin; hyoscine patches or glycopyrronium bromide
Cataplexy Tricyclic antidepressants; CNS stimulants


Anticholinergic drugs; benzodiazepines; botulinum toxin (selected cases only); gamma-aminobutyric acid derivatives (advanced dystonia)
Sleep disorders Melatonin; positive airway pressure
Movement restrictions Physical therapy
Seizures Antiepileptic drugs, according to seizure type
Psychiatric symptoms  
Bipolar disorder Mood stabilizers, such as sodium valproate
Catatonia Electroconvulsive therapy (ECT)
Depression Selective serotonin reuptake inhibitors (SSRIs)
Psychosis Atypical antipsychotics


Potential future therapies

Several other approaches to the management of NP-C have been or are currently being assessed for their potential use in the treatment of NP-C.



  • NP-C Registry
    The NP-C registry was launched in May 2009 to provide further valuable long-term data on real-world clinical experience of diagnosing and treating NP-C and understanding the natural history of the disease. The registry will capture data from patients with NP-C who are untreated or currently on treatment. The NP-C registry can be accessed at



  1. Patterson MC, Hendriksz CJ, Walterfang M, et al, on behalf of the NP-C Guidelines Working Group. Recommendations for the diagnosis and management of Niemann–Pick disease type C: An update. Mol Genet Metab 2012. 106(3):330-344.
  2. Zavesca® Summary of Product Characteristics.
  3. Patterson MC, et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007; 6: 765-772.
  4. Pineda M, et al. Miglustat in patients with Niemann-Pick disease Type C (NP-C): A multicenter observational retrospective cohort study. Molecular Genetics and Metabolism 2009; 98(3):243-249.
  5. Patterson MC, Vecchio D, Jacklin E, et al. Long-term miglustat therapy in children with Niemann-Pick disease type C. J Child Neurol 2009;25(3):300-5.
  6. Wraith JE, Vecchio D, Jacklin E, et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol Genet Metab 2010;99:351-7.